43 results about "Eosinophilic esophagitis" patented technology

The present invention relates to characterizing changes in mammalian bacterial gastrointestinal, cutaneous and nasal microbiota associated with antibiotic treatment and various disease conditions (such as asthma, allergy, obesity, metabolic syndrome, gastrointestinal reflux disease (GERD), eosinophilic esophagitis, gastro-esophageal junction adenocarcinomas (GEJAC), infections due to bacteria that are resistant to antibiotics, including Methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile, vancomycin-resistant enterococci, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of live bacterial inoculants that are capable of restoring healthy mammalian bacterial gastrointestinal, skin, and nasal microbiota.

Methods and compositions disclosed herein generally relate to methods of providing or enhancing a diagnosis of eosinophilic esophagitis (EE). In particular, the invention relates to obtaining a sample from a patient having at least one indication of EE, then quantifying from the sample an amount of one or more cytokines associated with EE or an mRNA corresponding to the cytokine or its receptor, wherein an altered level of the cytokine or mRNA correlates with a positive diagnosis of EE. An EE diagnosis can then be provided or enhanced, based upon the quantifying step. The invention further relates to diagnostic kits, tests, and/or arrays that can be used to quantify the one or more cytokines associated with EE or an mRNA corresponding to the cytokine or its receptor.

Provided herein are computer-based systems, software, and methods of using the same including a daily patient questionnaire, the questionnaire comprising: a question for determining whether the patient avoided solid food; a question for determining whether the patient had difficulty swallowing solid food; a question for determining what action the patient took to correct or relieve difficulty swallowing food; a question for determining the amount of pain the patient experienced while swallowing food; and a software module configured to apply an algorithm to answers to one or more of said questions to determine a score, wherein said score illustrates one or more selected from the group consisting of: (1) severity, intensity, or frequency of patient dysphagia; (2) suitability of a patient for a particular diagnostic tool, diagnostic method, or therapy for dysphagia; and (3) efficacy of a particular therapy for dysphagia.

The present invention provides methods for preventing or treating allergy. Also provided are methods for reducing the susceptibility to an allergen in a subject in need thereof. In certain embodiments, the subject has a disease or disorder selected from the group consisting of atopic dermatitis, asthma, allergic rhinitis, and eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.

The present invention provides methods for treating, preventing or reducing the severity of active eosinophilic esophagitis. In certain embodiments, the present invention provides methods of increasing esophageal distensibility. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4/interleukin-13 (IL-4/IL-13) pathway inhibitor such as an anti-IL-4R antibody.

Methods and compositions disclosed herein generally relate to determination of susceptibility to eosinophilic esophagitis, asthma, and/or allergic diseases, disorders, and/or pulmonary and/or upper gastrointestinal conditions arising therefrom and/or related thereto and the diagnosis, treatment, and/or management of eosinophilic esophagitis, asthma, and/or allergic diseases, disorders, and/or pulmonary and/or upper gastrointestinal conditions arising therefrom and/or related thereto. Embodiments of the invention relate to the association between genes and specific polymorphisms of genes with eosinophilic esophagitis. Embodiments of the invention can be used to determine and manage patient risk factors for development of eosinophilic esophagitis; this determination can then be used to diagnose eosinophilic esophagitis and to treat a patient diagnosed with eosinophilic esophagitis.

Embodiments of the invention are directed to methods of diagnosing eosinophilic gastritis (EG), or remission therefrom in a subject, wherein the methods include applying a sample from the subject to a diagnostic panel that contains selected markers for EG, analyzing the results thereof, and making a determination as to the EG status of the subject. Embodiments of the invention are also directed to methods of monitoring the pathological development or medical prognosis of EG in a subject. Embodiments of the invention are also directed to use of CDH26 as a marker for EG, eosinophilic esophagitis, or allergic inflammatory conditions. Embodiments of the invention also relate to the use of anti-CDH26-based therapeutics to treat allergic inflammatory conditions.

Disclosed are methods and compositions for preventing, treating, or ameliorating eosinophilic esophagitis (EoE) in an individual, comprising administering to the individual a therapeutically effective amount of at least one CRTH2 antagonist or a pharmaceutically acceptable salt thereof and at least one proton pump inhibitor (PPI) or a pharmaceutically acceptable salt thereof. Also disclosed are compositions comprising at least one CRTH2 antagonist or a pharmaceutically acceptable salt thereof and at least one proton pump inhibitor or a pharmaceutically acceptable salt thereof.

A method is described for diagnosing eosinophilic esophagitis by studying the levels of expression of novel markers, including ALOX15 or metabolites thereof, TNFAIP6, FLG, SLURP1, or CRISP3. Also described are methods for treating eosinophilic esophagitis.

Disclosed herein are pharmaceutical compositions and methods for oral, sublingual or subcutaneous administration comprising a sterically stabilized liposome carrier comprising: i) poly (ethylene glycol) distearoylphosphatidylethanolamine (PEG-DSPE); and ii) at least one of phosphatidylglycerol and phosphatidylcholine. Compositions and methods for treatment of food allergy and eosinophilic esophagitis are also described.

An endscopic imaging device is described that achieves longitudinal axis (z-axis) scanning into a tissue or sample, using a piezoelectric microactuator. In some configurations, additional lateral (xy-plane) scanning is also achieved, to allow for the creation of full three-dimensional imaging, ex vivo or in vivo. The techniques may be used to image and diagnosis allergic rhinitis and eosinophilic esophagitis in tissue.

Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.